HCM
INMB icon

Heights Capital Management’s INmune Bio INMB Stock Holding History

Heights Capital Management’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-60,978
Closed -$329K – 152
2024
Q3 		$329K Buy
+60,978
New +$434K 0.24% 43

Other funds holding INMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PP
Praetorian PR Rincon, Puerto Rico $275M AUM 84.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

Heights Capital Management's INMB Position: Q4 2024 in Review

Heights Capital Management sold out of INmune Bio (INMB) in Q4 2024, closing a stake of 60,978 shares — an estimated $329K sold.

Heights Capital Management first reported a position in INMB in Q3 2024 and held it in 1 quarter. The position peaked at $329K in Q3 2024. 73 funds tracked by Wall St. Rank hold INMB as of Q4 2024.

  • Heights Capital Management reported no remaining INmune Bio position as of Q4 2024 after selling out during the quarter.
  • Heights Capital Management sold 60,978 INmune Bio shares in Q4 2024, an estimated $329K.
  • Heights Capital Management first reported a position in INmune Bio in Q3 2024 and held it in 1 quarter.
  • Heights Capital Management's INmune Bio position peaked at $329K in Q3 2024.
  • 73 funds tracked by Wall St. Rank held INmune Bio as of Q4 2024.

Based on Heights Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.